Last reviewed · How we verify
APSCTC
APSCTC is a small molecule that acts as a selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2).
APSCTC is a small molecule that acts as a selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2). Used for Treatment of type 2 diabetes.
At a glance
| Generic name | APSCTC |
|---|---|
| Sponsor | Apsen Farmaceutica S.A. |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By inhibiting SGLT2, APSCTC reduces glucose reabsorption in the kidneys, leading to increased glucose excretion in the urine and decreased glucose levels in the blood. This mechanism is thought to contribute to its therapeutic effects in the treatment of type 2 diabetes.
Approved indications
- Treatment of type 2 diabetes
Common side effects
- Increased risk of genital mycotic infections
- Increased risk of urinary tract infections
- Hypotension
Key clinical trials
- Efficacy and Safety of APSCTC for the Treatment of Postsurgical Pain Due to Third Molar Extraction (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- APSCTC CI brief — competitive landscape report
- APSCTC updates RSS · CI watch RSS
- Apsen Farmaceutica S.A. portfolio CI